Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.
Baltimore, United States. In Psychopharmacology (berl), Feb 2016
OBJECTIVES: A model that considers the striatal adenosine A2A-dopamine D2 receptor heteromer as a key modulator of dopamine-dependent striatal functions (reward-oriented behavior and learning of stimulus-reward and reward-response associations) is introduced, which should explain most of the psychomotor and reinforcing effects of caffeine.
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-Induced Dyskinesias.
Québec, Canada. In Curr Neuropharmacol, Jan 2016
In the basal ganglia, mGlu5 receptor negative allosteric modulators also normalize the L-DOPA-induced changes of dopamine D2 receptors, their associated signalling proteins (ERK1/2 and Akt/GSK3) and neuropeptides (preproenkephalin, preprodynorphin) as well as the adenosine A2A receptors expression.
Purinergic signalling in brain ischemia.
Florence, Italy. In Neuropharmacology, Dec 2015
Evidence up to now in literature indicate that A2A receptor antagonists provide protection centrally by reducing excitotoxicity, while agonists at A2A (and possibly also A2B) and A3 receptors provide protection by controlling massive infiltration and neuroinflammation in the hours and days after brain ischemia.
Purine nucleosides in neuroregeneration and neuroprotection.
Lisbon, Portugal. In Neuropharmacology, Dec 2015
brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), is also focused considering the intimate relationship between some adenosine receptors, as is the case of the A2A receptors, and receptors for neurotrophins.
Adenosine receptors as drug targets--what are the challenges?
Boston, United States. In Nat Rev Drug Discov, 2013
However, only one adenosine receptor-specific agent--the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma)--has so far gained approval from the US Food and Drug Administration (FDA).